Activation of KRAS Mediates Resistance to Targeted Therapy in MET Ex on 14 Mutant Non-Small Cell Lung Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1640
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

P2.03-14 PKCi-PAK1 Pathway Modulates Sensitivity to Therapy in EGFR, KRAS Mutant and Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Atorvastatin Overcomes Gefitinib Resistance in KRAS Mutant Human Non-Small Cell Lung Carcinoma Cells

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2013English

Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer

Cancer Research
Cancer ResearchOncology
2017English

Activation of the Met Kinase Confers Acquired Drug Resistance in FGFR-targeted Lung Cancer Therapy

Oncogenesis
Cancer ResearchMolecular Biology
2016English

KRAS Mutation, KRAS–LCS6 Polymorphism, and Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2010English

A Decade of Targeted Therapy for Non-Small Cell Lung Cancer

2017English

Influence of EGFR-activating Mutations on Sensitivity to Tyrosine Kinase Inhibitors in a KRAS Mutant Non-Small Cell Lung Cancer Cell Line

PLoS ONE
Multidisciplinary
2020English

Targeted Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

SY2-4Development of Targeted Therapy for Advanced Non-Small Cell Lung Cancer With Rare Driver Oncogenes as RET or MET

Annals of Oncology
MedicineOncologyHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy